Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Tharimmune is a biotech company focused on developing therapies for inflammatory and immunologic conditions with high unmet needs. Its pipeline includes novel biologics, bispecific antibodies, and innovative delivery systems targeting liver-related pruritus, cancer, and immune checkpoints. The company leverages proprietary technologies, strategic collaborations, and a clinical-stage portfolio to address complex diseases, aiming to improve treatment efficacy and patient outcomes in high-value therapeutic areas.
This description was generated via AI from an annual report. Updated about 1 year ago.